Peritoneal Effluent MMP-2 and PAI-1 in Encapsulating Peritoneal Sclerosis

Deirisa Lopes Barreto,Dirk G. Struijk,Raymond T. Krediet
DOI: https://doi.org/10.1053/j.ajkd.2014.10.022
IF: 11.072
2015-05-01
American Journal of Kidney Diseases
Abstract:BACKGROUND: <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recently, the use of effluent matrix metalloproteinase 2 (MMP-2) and plasminogen activator inhibitor 1 (PAI-1) as potential biomarkers of peritoneal fibrosis has been demonstrated during longitudinal follow-up of incident peritoneal dialysis (PD) patients. This study focuses on effluent MMP-2 and PAI-1 as early diagnostic markers in the preceding years of patients who develop encapsulating peritoneal sclerosis (EPS).</AbstractText>STUDY DESIGN: <AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Diagnostic test study.</AbstractText>SETTINGS & PARTICIPANTS: <AbstractText Label="SETTINGS & PARTICIPANTS" NlmCategory="METHODS">PD patients who developed EPS were compared with controls using a 1:3 case-control design with a minimum PD duration of 57 months.</AbstractText>INDEX TESTS: <AbstractText Label="INDEX TESTS" NlmCategory="METHODS">Dialysate appearance rates of MMP-2 and PAI-1.</AbstractText>REFERENCE TEST: <AbstractText Label="REFERENCE TEST" NlmCategory="METHODS">EPS cases identified by 2 experienced nephrologists and a radiologist based on predefined criteria.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">11 patients developed EPS within our center. The time course of MMP-2 appearance rates, studied by means of a linear repeated-measures model 4 years prior to the diagnosis of EPS, showed no difference between long-term controls and patients with EPS. In contrast, higher PAI-1 appearance rates were found in patients with EPS compared with controls (P=0.01). At a lag time of 1 year prior to EPS diagnosis, time-specific receiver operating characteristic curve analyses indicated a discriminative ability for PAI-1 appearance rate of 0.77 (95% CI, 0.63-0.91). A discriminative capacity was absent for those of MMP-2.</AbstractText>LIMITATIONS: <AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Low event rate of EPS prevented independent validation in this single-center study.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Elevated levels of PAI-1 appearance rates are present in patients who develop EPS, pointing to progressive peritoneal fibrosis and sclerosis. The PAI-1 appearance rate has fair discriminative capacity from 3 years prior to EPS diagnosis. Therefore, effluent PAI-1 may aid in monitoring peritoneal fibrosis and serve as a biomarker for EPS.</AbstractText>
What problem does this paper attempt to address?